reason report
solid outlook portfolio acceler outperform pt
bottom line yesterday result modestli
lower revenu earn forecast alexion
account slower strensiq kanuma growth howev
overal view compani stock remain strongli posit
trajectori two import revenu driver
gener myasthenia gravi gmg launch ultomiri
convers track strongli line ahead
base chang revenu earn estim
lower price target reiter
outperform rate compani stock alexion enter
period intens invest expans portfolio
address market compani advanc nine new indic
formul approv core complement franchis high titer
primari progress multipl sclerosi ppm also invest
three new molecul approach pivot trial
wilson diseas amyloidosi
addit compani recent ad sever novel technolog
enhanc complement portfolio
quarter compani disclos delay time
fcrn program due manufactur issu
affect revenu earn outlook compani
compani oper margin might come pressur due
increment expens associ initi multipl phase
trial earli expect investor appreci potenti
invest given rel high probabl success po
alexion also abl leverag sg expens revenu
growth remain strong ultomiri soliri mg nmo
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
yesterday alexion report financi result exceed
street expect top bottom line rais
product revenu earn guidanc soliri ultomiri
combin report sale ahead consensu
estim non-gaap ep
compar consensu estim
compani rais revenu ep guidanc
bracket latest consensu estim compani
indic gmg launch remain robust account
soliri revenu us gmg track becom largest
soliri indic us later year meanwhil ultomiri launch
paroxysm nocturn hemoglobinuria pnh addit upcom
approv soliri ultomiri maintain posit
estim convers onesourc enrol
achiev april
year price history/av daili volume mil
price target rate stock
outperform alexion lead compani develop commerci treatment
complement mediat diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia gravi
upcom label expans on-going launch ultomiri alexion final diversifi
portfolio beyond soliri two core ahu pnh indic believ alexion
increas revenu complement franchis competit threat soliri
overst view given long safeti efficaci histori soliri well
alexion progress develop improv version ultomiri greater potenc
longer half-lif conveni dose beyond complement kanuma strensiq continu
grow steadili still believ two product could combin contribut
expect oper margin maintain futur
find alexion well posit grow ep doubl digit next five year
revenu driven strong volum growth soliri gmg convers
ultomiri
alexion report total pro forma revenu consensu
expect driven strong sale soliri fast convers ultomiri soliri revenu
ahead consensu estim
soliri revenu increas y/i primarili driven recent launch indic gmg
estim gmg revenu grew q/q basi account
soliri us sale volum basi soliri increas y/i ultomiri report strong
sale ahead consensu also ahead estim ultomiri
start strong convers soliri first full quarter sinc fda approv
track achiev manag convers goal us pnh patient within two year
launch april percentag us pnh patient enrol alexion onesourc
hub ultomiri number start ultomiri reach signific
increas month ago much steeper increas convers report
quarterli earn call number suggest us us
pnh indic convers hurdl achiev well year-end
strensiq revenu consensu estim strensiq sale
increas y/i y/i volum basi kanuma revenu
consensu estim metabol busi combin
report sale quarter higher growth volum net sale due price
headwind sequenti declin kanuma came drop ex-u market outsid
us eu apac may attribut neg fx effect especi turkey
ep also driven strong soliri ultomiri perform total non-gaap
expens consensu estim
 expens consensu estim
sg came larg in-lin expect vs consensu vs estim
alexion paid tax rate averag dilut share count million
quarter report non-gaap ep well consensu estim
well estim
guidanc increas modestli alexion provid updat total revenu guidanc
increas compar initi guidanc announc earn
call recent consensu initi estim
soliris/ultomiri guidanc also consensu estim
initi estim total metabol revenu guidanc
consensu expect alexion expect expens revenu
sg expens revenu result oper margin non-
basi bracket consensu oper margin compani expect non-
dilut ep rang bracket recent consensu estim
initi estim
strengthen pipelin provid meaning catalyst path alexion announc
call file ultomiri ahu fda april also guid file
addit indic eu japan later addit recent regulatori file
ultomiri eu japan pnh alexion also file approv soliri nmo
us pdufa date eu japan orphan drug prioriti review grant alexion
clinic pipelin includ phase trial ultomiri pnh ahu children
adolesc ultomiri subcutan per week pnh ahu ultomiri gmg initi
gmg nmo formerli wilson diseas
warm autoimmun hemolyt anemia gmg intend start
phase trial late earli earli clinic program includ subq
ultomiri primari progress multipl sclerosi ppm amyotroph later sclerosi
al bi-specif subq
well preclin collabor dicerna op zealand complement pharma mani
emerg program enter pivot pre-pivot trial earli result
expect see invest increas significantli next year
controversi competit pnh ahu call compani discuss
controversi efficaci soliris/ultomiri correct anemia pnh patient
particularli compar competitor apelli mp biosimilar
regeneron op chugai modifi long act antibodi
competit threat alexion core busi soliris/ultomiri contribut
total revenu alway one core controversi decemb last year apelli
report phase trial result treatment pnh data suggest
hemoglobin increas patient patient baselin hemoglobin level
less month compar alexion studi show hb benefit baselin
hb benefit studi baselin dont view direct competitor
soliris/ultomiri least current data accord studi soliri
abl keep patient treatment nave switch stabl hemoglobin level
though provid extra benefit grant much extra clinic benefit
patient seem like control intravascular hemolysi effect soliri
ultomiri alexion also point apelli select enrol subset pnh patient
anemia absenc bone marrow failur seem potenti label might
includ small subset patient apelli expand recruit criteria
manufactur issu delay fcrn program call alexion provid
updat manufactur issu identifi
trial compani found impur formul use on-going trial
impur associ sever inject reaction observ trial
alexion modifi final purif step remov element final formul
chang requir addit valid reason compani delay time
next trial initi indic compani suggest
conduct combin dose-rang phase ii/iii pivot trial one integr studi
warm autoimmun hemolyt anemia waiha begin sinc program yet
show proof concept expect investor react neg disclosur although
affect competit compar late stage clinic develop
moder revenu cut metabol busi decreas pt
base recent quarter made chang revenu earn forecast
decreas price target total revenu forecast decreas
increas futur year primarili due lower
estim metabol busi soliri ou sale soliri us sale increas
futur year base excel life cycl manag reduc
slightli revis estim oper expens estim ebit
higher pro forma ep forecast higher recent consensu
later year base chang updat price target
maintain outperform rate alexion stock
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
growth adjust near-term earn multipl ratio discount
cash flow dcf use rel multipl similar growth compani ep
appli ep estim alexion give fair valu stock use
expect ep compound-annual-growth-rate alexion period current averag
ratio larg molecul large-cap biotech give ep multipl
discount multipl compress alexion appli
ep estim give fair valu final dcf use termin growth rate post
give current valu averag three valuat methodolog
pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica myasthenia
gravi novel rare diseas medicin time horizon forecast
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand
type event
event trial detail
date known
up/down
expect
combin waiha pv ph data
present
combin waiha pv ph data
present
european hear com patent
sound like patient clinic poc studi
biomark endpoint prelud larger pivot
bridg trial pnh indic
svb leerink llc research compani file
analysi stock price svb leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biopharma co
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
sale non-gaap
share count period dilut
guidanc
late stage pipelin program includ
late stage pipelin program exclud
